Literature DB >> 16765341

The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox.

Karine Chantrel-Groussard1, François Gaboriau, Nicole Pasdeloup, René Havouis, Hanspeter Nick, Jean-Louis Pierre, Pierre Brissot, Gérard Lescoat.   

Abstract

By comparing the antiproliferative effect of the iron chelators ICL670A and O-trensox in the human hepatoma cell line HUH7 and human hepatocyte cultures, we have shown that ICL670A decreased cell viability, inhibited DNA replication and induced DNA fragmentation more efficiently than O-trensox. O-trensox and ICL670A induced a cell cycle blockade in G0-G1 and S phases respectively. In parallel, ICL670A inhibited polyamine biosynthesis by decreasing ornithine decarboxylase and spermidine/spermine N(1)-acetyltransferase activities. O-trensox increased polyamine biosynthesis and particularly putrescine level by stimulating spermidine-spermine N(1)-acetyltransferase activity which could activate the polyamine retro-conversion pathway. Moreover, the two chelators exhibit some cytotoxic effect in the two culture models; ICL670A was more cytotoxic than O-trensox and higher concentrations of the two chelators were necessary to induce a cytotoxicity in primary cultures versus hepatoma cells. These results suggested that ICL670A has the most efficient antitumoral effect, blocks cell proliferation by a pathway different of O-trensox and may constitute a potential drug for anticancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16765341     DOI: 10.1016/j.ejphar.2006.05.001

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Signs of deferasirox genotoxicity.

Authors:  Hasan Basri Ila; Mehmet Topaktas; Mehmet Arslan; Mehmet Büyükleyla
Journal:  Cytotechnology       Date:  2013-07-26       Impact factor: 2.058

2.  Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Authors:  Pascal Rouge; Alexandra Dassonville-Klimpt; Christine Cézard; Stéphanie Boudesocque; Roger Ourouda; Carole Amant; François Gaboriau; Isabelle Forfar; Jean Guillon; Emmanuel Guillon; Enguerran Vanquelef; Piotr Cieplak; François-Yves Dupradeau; Laurent Dupont; Pascal Sonnet
Journal:  Chempluschem       Date:  2012-11-01       Impact factor: 2.863

Review 3.  The role of iron in tumour cell proliferation.

Authors:  Juan Luis Steegmann-Olmedillas
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

4.  Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments.

Authors:  Takahiro Yamasaki; Issei Saeki; Isao Sakaida
Journal:  Hepatol Int       Date:  2014-01-29       Impact factor: 6.047

5.  Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.

Authors:  Sergio A Loza-Rosas; Alexandra M Vázquez-Salgado; Kennett I Rivero; Lenny J Negrón; Yamixa Delgado; Josué A Benjamín-Rivera; Angel L Vázquez-Maldonado; Timothy B Parks; Charlene Munet-Colón; Arthur D Tinoco
Journal:  Inorg Chem       Date:  2017-06-23       Impact factor: 5.165

6.  Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

Authors:  G Lescoat; K Chantrel-Groussard; N Pasdeloup; H Nick; P Brissot; F Gaboriau
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

7.  Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Authors:  S J Ford; P Obeidy; D B Lovejoy; M Bedford; L Nichols; C Chadwick; O Tucker; G Y L Lui; D S Kalinowski; P J Jansson; T H Iqbal; D Alderson; D R Richardson; C Tselepis
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 8.  Iron deprivation in cancer--potential therapeutic implications.

Authors:  Jessica L Heath; Joshua M Weiss; Catherine P Lavau; Daniel S Wechsler
Journal:  Nutrients       Date:  2013-07-24       Impact factor: 5.717

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  Effects of oral iron chelator deferasirox on human malignant lymphoma cells.

Authors:  Jong Gwon Choi; Jung-Lim Kim; Joohee Park; Soonwook Lee; Seh Jong Park; Jun Suk Kim; Chul Won Choi
Journal:  Korean J Hematol       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.